Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Drebrin 1 (DBN1) is a cytoplasmic, actin-binding protein crucial for neuronal development, synaptic function, and cytoskeleton organization. Encoded by the DBN1 gene, it exists as two major isoforms—drebrin A (neuron-specific, found predominantly in adult brain dendritic spines) and drebrin E (expressed earlier in development and in non-neuronal cells)[2][3][5]. Drebrin regulates the morphology and plasticity of dendritic spines and is involved in intercellular junctions and immune synapses[2][3][4]. It acts by stabilizing F-actin and coordinating actin–microtubule interactions, such as binding to microtubule plus-end proteins like EB1/EB3 and forming unique F-actin scaffolds for molecular signaling[3][4]. Reduction of drebrin has been associated with synaptic loss and cognitive impairment in Alzheimer’s disease and Down syndrome[3][4][5]. Drebrin is not a typical pharmacological target such as a receptor or enzyme, and there are no known drugs directly targeting it, but it plays a key mechanistic role in diseases linked to cytoskeletal dysregulation and neuronal connectivity[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Drebrin 1 (DBN1).